HomeREGULATORY
REGULATORY

Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients
(Sep.4.2017)

The Ministry of Health, Labor and Welfare (MHLW) reported its plan to approve an additional indication for Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) to its advisory panel on September 1, paving the way for its approval for all SMA patients expected by the end of this month ...
(LOG IN FOR FULL STORY)

News Calendar